bluebird bio: Market Fails To React To Impressive Data On Lenti-D Gene Therapy For CALD Seeking Alpha, 23 Sep 2019 bluebird bio recently presented impressive Phase II/III data from their Lenti-D program from cerebral adrenoleukodystrophy (CALD…